A warning on D.E.I.: The Trump administration on Wednesday threatened tens of thousands of federal employees with “adverse consequences” if they fail to report on colleagues who defy orders to purge ...

Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President Donald Trump's secretary of the U.S. Department of Health and Human ...

Mr. Kennedy has referred clients to the firm in cases claiming injuries from the Gardasil vaccine, a Merck product that is meant to prevent cervical cancer that can be caused by the human ...

Kennedy Jr.'s secretary of the Department of Health and Human Services (HHS) confirmation hearing and how pharma stocks like Pfizer (PFE) and Merck (MRK) may be impacted: "There's been a lot of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The latest version of Keytruda could eventually capture between 30% and 40% of the market for the original, Merck CEO Rob Davis said at the JPMorgan Healthcare Conference in San Francisco on Monday.

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans to overcome high-profile losses of exclusivity (LOEs) slated to dent sales through the end of the ...

Welireg generated $139 million in sales during 2024’s third quarter and is the only approved HIF-2α inhibitor in the U.S. Merck’s application in PPGL is based on objective response rate and ...

The Chinese contract drugmaker will sell its vaccine factory in Dundalk, Ireland, to U.S.-based Merck for about $500 million, it said in an exchange filing late Monday. The facility, with a net ...

Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...

In a presentation at JPMorgan’s healthcare investment conference in San Francisco late Monday, Merck executives presented a rosy picture as the company heads toward the 2028 patent expiration.